Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 26908728.
- Also identified by DOI 10.1093/infdis/jiw047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Understanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining vaccine policy. 176 078 members of Kaiser Permanente ≥60 years vaccinated with HZ vaccine and three matched unvaccinated members were included. Hazard ratios and 95% confidence intervals (CIs) associated with vaccination at each year following vaccination were estimated by Cox regression model. The effectiveness of HZ vaccine decreased from 68.7% (95% CI, 66.3%-70.9%) in the first year to 4.2% (95% CI, -24.0% to 25.9%) in the eighth year. This rapid decline in effectiveness of HZ vaccine suggests that a revaccination strategy may be needed, if feasible.
Medical subject headings
- Herpes Zoster
- Herpes Zoster Vaccine
- Policy Making